Published in Anesth Analg on August 04, 2010
Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation. Braz J Med Biol Res (2012) 0.81
Inpatient hemodialysis without anticoagulation in adults. Clin Kidney J (2014) 0.80
Protamine sulfate: crouching clot or hidden hemorrhage? Anesth Analg (2010) 0.75
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med (2010) 6.81
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology (2010) 2.55
Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol (2005) 2.54
Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion (2004) 2.51
Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg (2003) 2.31
Coagulopathy after cardiopulmonary bypass in Jehovah's Witness patients: management of two cases using fractionated components and factor VIIa. Anesth Analg (2007) 2.12
Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology (2010) 1.87
A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology (2005) 1.82
Innate immune lectins kill bacteria expressing blood group antigen. Nat Med (2010) 1.78
Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. Anesth Analg (2011) 1.77
Does perioperative systolic blood pressure variability predict mortality after cardiac surgery? An exploratory analysis of the ECLIPSE trials. Anesth Analg (2011) 1.77
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg (2010) 1.60
Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. Ann Thorac Surg (2005) 1.54
The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg (2008) 1.54
Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery. Anesthesiology (2016) 1.51
A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg (2005) 1.46
The effect and duration of prophylactic platelet transfusions before insertion of a central venous catheter in patients with bone marrow failure evaluated with point-of-care methods and flow cytometry. Anesth Analg (2014) 1.46
The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg (2009) 1.43
Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro. Thromb Res (2004) 1.42
Evaluation of dynamic parameters of thrombus formation measured on whole blood using rotational thromboelastometry in children undergoing cardiac surgery: a descriptive study. Paediatr Anaesth (2015) 1.42
Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. J Thorac Cardiovasc Surg (2012) 1.42
Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg (2006) 1.41
Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg (2006) 1.39
Hemoglobinopathies and clinical laboratory testing. MLO Med Lab Obs (2009) 1.39
Shotgun glycomics: a microarray strategy for functional glycomics. Nat Methods (2010) 1.37
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost (2015) 1.36
Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization. Crit Care Med (2007) 1.35
Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev (2011) 1.28
Concepts of blood transfusion in adults. Lancet (2013) 1.28
Infection, viral dissemination, and antibody responses of rhesus macaques exposed to the human gammaretrovirus XMRV. J Virol (2011) 1.28
Blood coagulation: hemostasis and thrombin regulation. Anesth Analg (2009) 1.24
Sepsis-induced disseminated intravascular coagulation, symmetrical peripheral gangrene, and amputations. Crit Care Med (2013) 1.12
Mapping of the human RNASEL promoter and expression in cancer and normal cells. J Interferon Cytokine Res (2005) 1.11
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA (2004) 1.07
A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. Transfusion (2011) 1.07
A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg (2007) 1.05
Falsely increased HCG in patients with high leukocyte counts. Clin Chem (2013) 1.05
Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg (2014) 1.05
Impact of percutaneous coronary intervention performance reporting on cardiac resuscitation centers: a scientific statement from the American Heart Association. Circulation (2013) 1.04
The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg (2005) 1.03
Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology (2008) 1.03
Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. Thromb Res (2007) 1.02
Management of hemorrhage in cardiothoracic surgery. J Cardiothorac Vasc Anesth (2013) 0.97
Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. Transfusion (2013) 0.96
Lessons from the aprotinin saga: current perspective on antifibrinolytic therapy in cardiac surgery. J Anesth (2009) 0.96
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol (2012) 0.95
Acute aortic dissection with intimal layer prolapse into the left ventricle. Anesth Analg (2007) 0.95
The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg (2004) 0.95
A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. Anesth Analg (2011) 0.94
Clevidipine in adult cardiac surgical patients: a dose-finding study. Anesthesiology (2002) 0.93
The role of thrombin and protease-activated receptors in pain mechanisms. Thromb Haemost (2010) 0.93
A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process. Microvasc Res (2011) 0.91
Impact of hemoglobin variants on Hb A1c interpretation: do we assume too much? MLO Med Lab Obs (2012) 0.91
Improved clot formation by combined administration of activated factor VII (NovoSeven) and fibrinogen (Haemocomplettan P). Anesth Analg (2008) 0.91
Bleeding and management of coagulopathy. J Thorac Cardiovasc Surg (2011) 0.90
Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery. J Anesth (2007) 0.89
Roles of thrombelastography and thromboelastometry for patient blood management in cardiac surgery. Transfus Med Rev (2013) 0.88
Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg (2013) 0.87
A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg (2008) 0.87
Electron microscopic evaluations of clot morphology during thrombelastography. Anesth Analg (2004) 0.87
The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth Analg (2002) 0.87
Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg (2010) 0.86
Clinical measures of heparin's effect and thrombin inhibitor levels in pediatric patients with congenital heart disease. Anesth Analg (2006) 0.86
Determination of the standard value of circulating blood volume during anesthesia using pulse dye-densitometry: a multicenter study in Japan. J Anesth (2005) 0.86
Evaluation and management of bleeding during cardiac surgery. Curr Hematol Rep (2005) 0.85
Treatment of persistent tachycardia with dexmedetomidine during off-pump cardiac surgery. Anesth Analg (2002) 0.85
Perioperative ischemic stroke in non-cardiovascular surgery patients. J Anesth (2010) 0.85
Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model. J Trauma (2010) 0.85
Reduced levels of fibrin (antithrombin I) and antithrombin III underlie coagulopathy following complex cardiac surgery. Blood Coagul Fibrinolysis (2008) 0.85
Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). Anesthesiology (2003) 0.85
The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. Anesth Analg (2002) 0.84
Activated recombinant factor VII in cardiac surgery. Curr Opin Anaesthesiol (2005) 0.84
Systemic thromboses after cardiopulmonary bypass: is it thrombin or antithrombin? Anesthesiology (2006) 0.84
Gender differences between predicted and measured propofol C(P50) for loss of consciousness. J Clin Anesth (2006) 0.84
Evaluation of low-dose propofol preadministration to attenuate vascular pain during induction of anesthesia. J Clin Anesth (2007) 0.83
Fluid therapy with hydroxyethyl starch for massive blood loss during surgery. J Anesth (2010) 0.83
The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry. Anesth Analg (2012) 0.83
Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology (2002) 0.83
An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates. Anesth Analg (2005) 0.82
In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma. J Cardiothorac Vasc Anesth (2009) 0.82
Pre-analytical effects of pneumatic tube transport on impedance platelet aggregometry. Platelets (2009) 0.82